NYSCF Announces Expansion of Scientific Leadership Team
Three top scientific and business professionals recently joined NYSCF, bolstering its leadership team:
- Melissa J. Nirenberg, MD, PhD, FAAN has joined NYSCF as its inaugural Chief Medical Officer
- Elizabeth Schwarzbach, PhD, will lead NYSCF’s partnering and collaboration efforts as Vice President of Business Development
- Michael Zdanowski will oversee NYSCF’s new GMP cell therapy manufacturing facility and operations as NYSCF Vice President of GMP Operations
“Melissa Nirenberg’s research and world-class clinical knowledge will help NYSCF and our collaborators realize the promise of stem cell research by bridging the gap between bench science and medical practice, ” said Susan L. Solomon, CEO and co-founder of NYSCF. “Liz Schwarzbach brings a wealth of experience to our partnering and business development efforts, which are essential to NYSCF’s next phase of growth, and Mike Zdanowski’s long standing expertise will allow us to reach our goal of bringing new cell therapies to patients. These three key additions to our leadership team will enable us to bring new and better treatments to the clinic.”
With an extensive background in both industry and academia in drug discovery and development, Dr. Schwarzbach will foster new partnerships and grow NYSCF’s role in the scientific and medical community. As NYSCF moves further into clinical and diagnostic stem cell applications, Dr. Schwarzbach will oversee collaborations with biotech, pharmaceutical, and academic research institutions.
Dr. Nirenberg, a long-time NYSCF collaborator and movement disorders specialist, brings her background as a physician-scientist to NYSCF, working with NYSCF scientists and external partners to translate their research into therapies and facilitate upcoming clinical trials.
As the Vice President of Good Manufacturing Practices, or GMP, Operations at the NYSCF Research Institute, Mr. Zdanowski will lead NYSCF’s GMP cell production effort to bring the most advanced and rigorous cell manufacturing capabilities to NYSCF, including process development, quality and regulatory compliance, and manufacturing.
All three professionals will play critical roles in the planning and execution of two cell therapy clinical trials that NYSCF is currently in the initial stage of with clinicians in New York City.